• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    2/1/23 4:30:58 PM ET
    $ADIL
    $ALGN
    $BGXX
    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 33.0% to $6.01 during Wednesday's after-market session. This security traded at a volume of 323.6K shares come close, making up 21.6% of its average volume over the last 100 days. The company's market cap stands at $6.1 million.
    • Lannett (NYSE:LCI) shares rose 15.74% to $0.62. The market value of their outstanding shares is at $26.2 million. As per the press release, Q2 earnings came out today.
    • Align Tech (NASDAQ:ALGN) shares rose 15.03% to $325.0. At the close, Align Tech's trading volume reached 121.5K shares. This is 11.8% of its average volume over the last 100 days. The company's market cap stands at $25.3 billion. The company's, Q4 earnings came out today.
    • Adial Pharmaceuticals (NASDAQ:ADIL) shares rose 12.69% to $0.53. Today's trading volume for this security ended up closing at 1.7 million shares, which is 1118.5 percent of its average volume over the last 100 days. The company's market cap stands at $14.2 million.
    • Nymox Pharmaceutical (NASDAQ:NYMX) stock rose 12.29% to $0.49. The market value of their outstanding shares is at $44.8 million.
    • Opthea (NASDAQ:OPT) stock increased by 10.66% to $5.81. The company's market cap stands at $294.1 million.

    Losers

    • Bright Green (NASDAQ:BGXX) shares fell 12.0% to $1.25 during Wednesday's after-market session. Trading volume for this security closed at 1.2 million, accounting for 398.9% of its average full-day volume over the last 100 days. The company's market cap stands at $211.6 million.
    • Calithera Biosciences (NASDAQ:CALA) shares decreased by 9.62% to $0.33. The market value of their outstanding shares is at $1.6 million.
    • Metacrine (NASDAQ:MTCR) stock decreased by 7.7% to $0.48. This security traded at a volume of 157.9K shares come close, making up 46.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $20.4 million.
    • Vera Therapeutics (NASDAQ:VERA) stock fell 7.43% to $7.85. The market value of their outstanding shares is at $217.1 million.
    • Purple Biotech (NASDAQ:PPBT) shares declined by 7.15% to $1.56. The market value of their outstanding shares is at $28.6 million.
    • Terns Pharma (NASDAQ:TERN) stock declined by 6.94% to $8.32. The company's market cap stands at $411.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $ALGN
    $BGXX
    $CALA

    CompanyDatePrice TargetRatingAnalyst
    Terns Pharmaceuticals Inc.
    $TERN
    3/25/2026Buy → Neutral
    H.C. Wainwright
    Align Technology Inc.
    $ALGN
    3/17/2026$200.00Equal Weight → Overweight
    Barclays
    Vera Therapeutics Inc.
    $VERA
    3/11/2026$88.00Peer Perform → Outperform
    Wolfe Research
    Align Technology Inc.
    $ALGN
    2/9/2026$200.00Hold → Buy
    HSBC Securities
    Terns Pharmaceuticals Inc.
    $TERN
    2/9/2026$58.00Outperform
    Leerink Partners
    Align Technology Inc.
    $ALGN
    12/9/2025$170.00Equal Weight
    Barclays
    Terns Pharmaceuticals Inc.
    $TERN
    11/4/2025$20.00Neutral → Buy
    H.C. Wainwright
    Terns Pharmaceuticals Inc.
    $TERN
    11/3/2025Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ADIL
    $ALGN
    $BGXX
    $CALA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.

    SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

    4/1/26 5:32:23 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Terns Pharmaceuticals Inc.

    S-8 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    3/30/26 5:55:46 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Terns Pharmaceuticals Inc.

    10-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    3/30/26 5:31:38 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ALGN
    $BGXX
    $CALA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LEVOFLOXACIN issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug LEVOFLOXACIN (SUPPL-11) with active ingredient LEVOFLOXACIN has changed to 'Approval' on 09/20/2024. Application Category: ANDA, Application Number: 205222, Application Classification: Labeling

    9/24/24 4:39:48 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MYCOPHENOLATE MOFETIL issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug MYCOPHENOLATE MOFETIL (SUPPL-7) with active ingredient MYCOPHENOLATE MOFETIL has changed to 'Approval' on 08/13/2024. Application Category: ANDA, Application Number: 214525, Application Classification: REMS

    8/15/24 4:43:42 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (ORIG-1) with active ingredient MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE has changed to 'Approval' on 07/15/2024. Application Category: ANDA, Application Number: 209941, Application Classification:

    7/17/24 4:37:21 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ALGN
    $BGXX
    $CALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Terns Pharmaceuticals downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Terns Pharmaceuticals from Buy to Neutral

    3/25/26 10:23:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Align Tech upgraded by Barclays with a new price target

    Barclays upgraded Align Tech from Equal Weight to Overweight and set a new price target of $200.00

    3/17/26 7:53:01 AM ET
    $ALGN
    Industrial Specialties
    Health Care

    Vera Therapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Vera Therapeutics from Peer Perform to Outperform and set a new price target of $88.00

    3/11/26 8:30:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ALGN
    $BGXX
    $CALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

    FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 equity inducement awards to three new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted 23,316 restricted stock units (the "RSUs"), in the aggregate, of Terns common stock to the new e

    4/2/26 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Align Technology to Announce First Quarter 2026 Results on April 29, 2026

    Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report first quarter 2026 financial results on Wednesday, April 29, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com. Following the press release, Align will host a conference call to discuss its financial results. The conference call will be

    4/1/26 4:23:00 PM ET
    $ALGN
    Industrial Specialties
    Health Care

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 56,850 shares of Class A common stock and restricted stock units (RSUs) underlying 42,403 shares of Class A common stock to Jane Wright-Mitchell, Vera's new Chief Legal Officer under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq List

    3/27/26 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ALGN
    $BGXX
    $CALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF LEGAL & REGULATORY Coletti Julie Ann bought $4,606 worth of shares (42 units at $109.66), increasing direct ownership by 0.59% to 7,110 units (SEC Form 4)

    4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)

    8/1/25 5:58:45 PM ET
    $ALGN
    Industrial Specialties
    Health Care

    PRESIDENT AND CEO Hogan Joseph M bought $996,131 worth of shares (7,576 units at $131.49), increasing direct ownership by 4% to 184,945 units (SEC Form 4)

    4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)

    8/1/25 4:05:18 PM ET
    $ALGN
    Industrial Specialties
    Health Care

    $ADIL
    $ALGN
    $BGXX
    $CALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kuriakose Emil

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    4/2/26 6:15:57 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Efron Gil

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    3/31/26 7:48:40 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 3 filed by new insider Lankry Shai S

    3/A - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    3/30/26 5:30:39 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ALGN
    $BGXX
    $CALA
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

    BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. "Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "As we near the potential launch of

    3/25/26 7:30:00 AM ET
    $PCVX
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Announces CEO Transition

    Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed

    3/13/26 8:04:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Christopher Hite to Board of Directors

    BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors. "It is a pleasure to welcome Chris to our Board of Directors at this exciting juncture in Vera Therapeutics' trajectory as we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy," sa

    3/5/26 9:00:22 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ALGN
    $BGXX
    $CALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 7:00:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 5:51:38 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ALGN
    $BGXX
    $CALA
    Financials

    Live finance-specific insights

    View All

    Align Technology to Announce First Quarter 2026 Results on April 29, 2026

    Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report first quarter 2026 financial results on Wednesday, April 29, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com. Following the press release, Align will host a conference call to discuss its financial results. The conference call will be

    4/1/26 4:23:00 PM ET
    $ALGN
    Industrial Specialties
    Health Care

    Align Technology Announces Fourth Quarter and Fiscal 2025 Financial Results

    Q4'25 record total revenues of $1,047.6 million, up 5.2% sequentially and up 5.3% year-over-year. Q4'25 Systems and Services revenues up 10.3% sequentially, and up 4.2% year-over-year, reflecting continued iTero Lumina™ upgrades and higher volume across all regions, and higher services revenues. Q4'25 Clear Aligner revenues up 4.0% sequentially and up 5.5% year-over-year. Q4'25 record Clear Aligner volumes of 676.9 thousand cases, up 4.5% sequentially, and up 7.7% year-over-year, driven by strength in the EMEA, Latin America and Asia Pacific regions and stability in North America. Q4'25 Clear Aligner volumes up 8.9% year-over-year in the Orthodontic channel, and up 5.3% year-over-year in

    2/4/26 4:06:00 PM ET
    $ALGN
    Industrial Specialties
    Health Care

    Align Technology to Announce Fourth Quarter and 2025 Results on February 4, 2026

    Align Technology, Inc. (NASDAQ:ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 4, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (2:00 p.m. MT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com. Following the press release, Align will host a conference call to discuss its financial results. The confere

    1/2/26 8:30:00 AM ET
    $ALGN
    Industrial Specialties
    Health Care